目的：主要是探索AD患者血浆中的tau与认知损害, CSF生物标志物(Aβ和tau),脑萎缩，脑代谢有无关系。
简介：患者来自2大研究：第一个就是ADNI——AD患者179例,MCI患者195例,认知正常对照189例；以及BioFINDER研究的AD、MCI、SCI患者人群。
结果：血浆tau升高与AD痴呆,CSF-tau升高,CSF-Aβ降低有微弱关系。ADNI随访研究提示有一定的预测价值。但是，与正常人群的重叠率太高，所以并不支持对于个体的疾病进展预测。
This study is the largest published on plasma tau,but it is not without limitations.
ADNI and BioFINDER samples were handled with different protocols and analyzed at different laboratories with different kit lots, which may have contributed to the varying results. Some ADNI participants had plasma tau below the lower limit of quantification of the assay (14 CNs, 11 patients with MCI, 10 patients with AD).
These measurements are uncertain but they were included because excluding them would have biased the data toward higher plasma tau (excluding them did not change the main results, data not shown). Another limitation is that we used only one plasma tau assay. It is possible that other assays capture tau fragments that are less sensitive to peripheral degradation and more likely to reflect AD pathology. A final limitation is that we did not covary for copathologies that may affect plasma tau levels
閱讀更多 徐俊主任醫師 的文章
